CD140a Antibodies: A Cornerstone Tool for Cell Biology Research – Powered by ANT BIO PTE. LTD.

1. Concept

CD140a, also known as platelet-derived growth factor receptor alpha (PDGFRα), is a key member of the type III tyrosine kinase receptor superfamily. Its structure comprises an extracellular domain with five immunoglobulin-like ligand-binding regions, a transmembrane segment, and an intracellular tyrosine kinase domain critical for signal transduction. CD140a antibodies are highly specific immunoglobulins designed to recognize and bind distinct epitopes on the CD140a molecule, serving as indispensable tools in cell biology research.

Classified into monoclonal (uniform, high-specificity) and polyclonal (multi-epitope recognition, enhanced sensitivity) variants, these antibodies are produced via hybridoma or recombinant DNA technology. Their quality—evaluated by specificity, affinity, and titer—directly dictates experimental reliability. CD140a antibodies enable precise cell identification, signal pathway analysis, and disease model construction, making them versatile assets across stem cell research, developmental biology, oncology, and fibrosis studies.

2. Research Frontiers

Cutting-edge research involving CD140a antibodies has expanded into diverse high-impact areas, driving innovations in basic and translational science:

• Stem Cell and Mesenchymal Research: CD140a has become a gold-standard marker for isolating mesenchymal stem cells (MSCs) via flow cytometry or immunomagnetic sorting. Recent studies confirm that CD140a-positive MSCs exhibit >85% osteogenic, chondrogenic, and adipogenic differentiation efficiency—outperforming unsorted cell populations.
• Signal Transduction Mechanisms: Advanced applications of CD140a antibodies (including phospho-specific variants) have enabled real-time tracking of PDGF pathway activation. Researchers now quantify receptor autophosphorylation kinetics, revealing peak activation within 5 minutes of ligand binding and subsequent downstream cascade regulation.
• Disease Model Refinement: In tumor research, CD140a antibodies facilitate the isolation of cancer-associated fibroblasts (CAFs) from tumor stroma, enabling more accurate tumor microenvironment modeling. In fibrosis studies, they quantify PDGFRα-positive myofibroblast accumulation, which correlates directly with disease severity.
• Antibody Engineering: Novel technologies such as nanobodies and bispecific antibodies are enhancing CD140a antibody performance, reducing non-specific binding while maintaining high affinity—opening avenues for ultra-sensitive detection and refined cell sorting.

3. Research Significance

CD140a antibodies address critical needs in cell biology research and translational medicine:

• Fundamental Science Advancements: They deepen understanding of cell proliferation, differentiation, and tissue development by unlocking PDGFRα-mediated signaling pathways and stem cell biology.
• Disease Mechanism Elucidation: By enabling precise identification of pathogenic cell populations (e.g., CAFs, activated myofibroblasts), these antibodies reveal key drivers of cancer progression and fibrosis, laying the groundwork for targeted therapies.
• Translational Potential: CD140a antibodies show promise as diagnostic biomarkers, with ongoing research exploring their utility in disease staging and prognosis assessment.
• Experimental Reproducibility: High-quality CD140a antibodies ensure consistent, reliable results across studies, accelerating scientific collaboration and knowledge translation.

4. Related Mechanisms, Research Methods, and Product Applications

Related Mechanisms

CD140a antibodies exert their research utility by leveraging the molecular function of PDGFRα:

• Ligand-Binding and Activation: PDGFRα dimerizes and autophosphorylates upon binding PDGF ligands, activating downstream signaling cascades (e.g., PI3K-AKT, MAPK) that regulate cell growth, migration, and differentiation.
• Cell-Specific Expression: CD140a is selectively expressed on MSCs, fibroblasts, glial cells, and pathogenic populations like CAFs—enabling targeted identification and isolation.

Research Methods

CD140a antibodies support a range of core research techniques:

• Cell Identification and Sorting: Flow cytometry and immunomagnetic sorting for isolating pure CD140a-positive cell populations (e.g., MSCs, CAFs) from heterogeneous samples.
• Signal Pathway Analysis: Co-immunoprecipitation to identify PDGFRα-interacting proteins, and Western blot to detect CD140a (≈170 kDa) and its phosphorylated forms.
• Disease Model Research: Immunohistochemistry to localize PDGFRα-positive cells in tissue sections, and quantitative analysis of cell accumulation in tumor or fibrosis models.
• Functional Assays: Evaluation of cell differentiation potential (osteogenic, chondrogenic, adipogenic) and signaling pathway activation kinetics.

Product Applications by ANT BIO PTE. LTD.

ANT BIO PTE. LTD., via its sub-brand STARTER (specializing in high-performance antibodies), offers a curated portfolio of CD140a antibodies validated for reliability and specificity. These products exhibit:

• High Specificity and Functional Recognition: Rigorously validated by flow cytometry and immunohistochemistry, they specifically bind human or mouse CD140a (PDGFRα) with no cross-reactivity, enabling precise identification of target cell types.
• Excellent Stability and Batch Consistency: Manufactured under strict quality control, ensuring minimal intra- and inter-batch variation for reproducible results.

Key application scenarios include:

• Stromal Cell and Stem Cell Research: Study of MSC development, differentiation, and preadipocyte/fibroblast biology.
• Fibrosis Mechanism Exploration: Investigation of PDGFRα-positive cell activation and extracellular matrix deposition in pulmonary, liver, or renal fibrosis.
• Tumor Microenvironment Studies: Analysis of CAF distribution and function in cancer stroma.
• Developmental Biology: Research on mesenchymal tissue formation and organogenesis during embryogenesis.

5. Brand Mission

At ANT BIO PTE. LTD., our mission is to empower global innovative pharmaceutical companies, research institutions, and life science researchers with high-quality, high-value biological reagents and comprehensive solutions. Leveraging state-of-the-art technology platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development systems (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—we strive to accelerate scientific discovery and translational research. Our sub-brands (Absin for general reagents and kits, STARTER for antibodies, and UA for recombinant proteins) synergize to address diverse research needs, contributing to breakthroughs in cell biology, developmental biology, oncology, and fibrosis research. With certifications including EU 98/79/EC, ISO9001, and ISO13485, we uphold the highest standards of quality and reliability to support our mission of advancing human health through science.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.